The influence of established and new antiepileptic drugs on visual perception: II. A controlled study in patients with epilepsy under long-term antiepileptic medication

Epilepsy Research

Volumn 29, Issue 1, 1997, Pages 49-58

  Steinhoff, Bernhard J ^a   Freudenthaler, Nóra ^a   Paulus, Walter ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Antiepileptic drug toxicity; Visual disturbances

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; GABAPENTIN; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ARTICLE; COLOR VISION; CONTROLLED STUDY; DRUG BLOOD LEVEL; EPILEPSY; EYE TOXICITY; HUMAN; MAJOR CLINICAL STUDY; NEUROTOXICITY; PRIORITY JOURNAL; VISUAL ADAPTATION; VISUAL DISORDER; VISUAL THRESHOLD;

ADAPTATION, OCULAR; ADULT; ANTICONVULSANTS; CASE-CONTROL STUDIES; COLOR PERCEPTION; DRUG ADMINISTRATION SCHEDULE; EPILEPSY; FLICKER FUSION; HUMANS; SENSORY THRESHOLDS; VISUAL PERCEPTION;

EID: 0030732044     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(97)00062-4     Document Type: Article

References (30)

1. Bayer A. Retinale Funktionsstörungen bei Patienten unter antikonvulsiver Therapie. Medical Thesis, University of Tübingen, 1991.
2. Bayer A., Thiel H.-J., Zrenner E., Paulus W., Ried S., Schmidt D. Colour vision deficiencies and enhanced sensitivity to glare in epileptic patients treated with carbamazepine and phenytoin: ocular side effects of antiepileptic drug. Nervenarzt. 66:1995;89-96.
3. Bayer A., Thiel H.-J., Zrenner E., Paulus W., Ried S., Schmidt D. Sensitive physiological tests for ocular side effect of drugs: antiepileptics. Ophthalmologe. 92:1995;182-190.
4. Paulus W., Schwarz G., Steinhoff B.J. The effect of anti-epileptic drugs on visual perception in patients with epilepsy. Brain. 119:1996;539-549.
5. Tomson T., Nilsson B.Y., Levi R. Impaired visual contrast sensitivity in epileptic patients treated with carbamazepine. Arch Neurol. 45:1988;897-900.
6. Steinhoff BJ, Freudenthaler N, Paulus W. The influence of established and new antiepileptic drugs on visual perception. I. A placebo-controlled, double-blind, single-dose study in healthy volunteers. Epilepsy Res 1997;29:35-47.
7. Slaughter M.M., Bai S.-H. Baclofen's suppression of epileptiform-like activity: a retinal model. Neurosci Res Suppl. 8:1988;S217-S229.
8. Grove J., Schechter P.J., Tell G., Koch-Weber J., Sjoerdsma A., Warter J.M., Marescaux C., Rumbach L. Increased gamma-amino-butyric acid (GABA), homocarnosine and beta-alanine in cerebrospinal fluid of patients treated with gamma-vinyl GABA (4-amino-hex-5-enoic). Life Sci. 28:1981;2431-2439.
9. Lippert B., Metcalf B.W., Jung M.J., Casara P. 4-amino-hex-5-enoic acid, a selective catalytic inhibitor of 4-aminobutyric acid aminotransferase in mammalian brain. Eur J Biochem. 74:1997;441-445.
10. Löscher W., Schmidt D. Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation? Epilepsy Res. 17:1994;95-134.
11. Ben-Menachem E., Hamberger A., Mumford J. Effect of long-term vigabatrin therapy on GABA and other amino acid concentrations in the central nervous system. Epilepsy Res. 16:1993;241-243.
12. Ben-Menachem E., Persson L., Schechter P.J., Haegele K.D., Huebert N., Hardenberg J., Dahlgren L., Mumford J.P. Effects of single doses of vigabatrin on CSF concentrations of GABA, homocarnosine, homovanillic acid and 5-hydroxyindoleacetic acid in patients with complex partial epilepsy. Epilepsy Res. 2:1988;96-101.
13. Kälviäinen K., Halonen T., Pitkänen A., Riekkinen P.J. Amino acid levels in the cerebrospinal fluid of newly diagnosed epileptic patients: effect of vigabatrin and carbamazepine monotherapies. J Neurochem. 60:1993;1244-1250.
14. HNMR measurements of GABA levels in human brain in vivo. Proc Natl Acad Sci USA. 90:1993;5562-5566.
15. Löscher W., Siemes H. Cerebrospinal fluid γ-aminobutyric acid levels in children with different types of epilepsy: effect of anticonvulsant treatment. Epilepsia. 26:1985;314-319.
16. 1H]magnetic resonance spectroscopy and valproate [Abstract]. Epilepsia. 36(Suppl. 3):1995;S145-S146.
17. Löscher W. Valproate enhances GABA turnover in the substantia nigra. Brain Res. 501:1989;198-203.
18. Löscher W. Valproinsäure: Pharmakodynamische Wirkungen und biochemische Wirkungsmechanismen. In: Krämer G, Laub MC, editors. Valproinsäure. Berlin: Springer, 1992: 3-23.
19. Kerwin R.W., Olpe H.R., Schmutz M. The effect of sodium-n-dipropyl acetate on GABA dependent inhibition in rat cortex in vivo. Br J Clin Pharmacol. 71:1980;545-551.
20. Henriksen O., Johannessen S.I. Clinical and pharmakokinetic observations on sodium valproate: a 5 year follow-up study in 100 children with epilepsy. Acta Neurol Scand. 65:1982;504-523.
21. Brown S.D., Wolf H.H., Swinyard E.A., Twyman R.E., White H.S. The novel anticonvulsant topiramate enhances GABA-mediated chloride flux [Abstract]. Epilepsia. 34(Suppl 2):1993;S122-S123.
22. White H.S., Brown S.D., Skeen G.A., Wolf H.H., Twyman R.E. The anticonvulsant topiramate displays a unique ability to potentiate GABA- evoked chloride channels [Abstract]. Epilepsia. 36(Suppl. 3):1995;S39.
23. Stables J.P., Bialer M., Johannessen S.I., Kupferberg H.J., Levy R.H., Loiseau P., Perucca F. Progress report on new antiepileptic drugs. A summary of the second Eilat conference. Epilepsy Res. 22:1995;235-246.
24. Ott H, Kranda H. Flicker Techniques in Psychopharmacology. Weinheim: Beltz, 1982.
25. Löscher W., Honack D., Taylor C.P. Gabapentin increases aminooxyacetic acid-induced GABA accumulation in several regions in rat brain. Neurosci Lett. 128:1991;150-154.
26. Petroff O.A.C., Rothman D.L., Behar K.L., Lamoureux D., Mattson R.H. The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann Neurol. 339:1996;95-99.
27. Ziemann U, Lönnecker S, Steinhoff BJ, Paulus W, Effects of antiepileptic drugs on motor cortex excitability in humans: A transcranial magnetic stimulation study. Ann Neurol 1996;40:367-378.
28. Macdonald RL, Meldrum BS. Principles of antiepileptic drug action. In: Levy RH, Mattson RH, Meldrum BS. editors. Antiepileptic Drugs, 4th ed. New York: Raven Press, 1995: 61-77.
29. Zrenner E., Nowicki J. Medikamentös induzierte Funktionsstörungen der Zapfenfunktion und Zapfeninteraktion. Fortschr Ophthalmol. 82:1985;589-594.
30. Petroff O.A.C., Rothman D.L., Behar K.L., Mattson R.H. Low brain GABA level is associated with poor seizure control. Ann Neurol. 40:1996;908-911.